PMID- 20656513
OWN - NLM
STAT- MEDLINE
DCOM- 20110909
LR  - 20110706
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
VI  - 20
IP  - 4
DP  - 2011 Jul-Aug
TI  - Antiplatelet agents are risk factors for cerebellar hemorrhage in patients with 
      primary intracerebral hemorrhage.
PG  - 346-51
LID - 10.1016/j.jstrokecerebrovasdis.2010.02.005 [doi]
AB  - Some reports have suggested that the location of primary intracerebral hemorrhage 
      (ICH) is affected by oral antithrombotic agents (ATs). This is important, given 
      the increasing use of ATs to treat arteriosclerotic disease. The aim of this 
      study was to explore whether oral AT therapy increase the incidence of any 
      specific location of primary ICH. A retrospective, single-institution study 
      involving 410 Japanese patients with primary ICH was conducted between July 2003 
      and June 2009. Bivariate analyses (ie, Fisher's exact 2-tailed test, Student's t 
      test, Welch's test, Wilcoxon's rank-sum test, Pearson's chi(2) test) and 
      multivariate logistic regression analysis were performed for clinical 
      characteristics of these patients. Of the 410 patients, 20% were taking ATs 
      before the onset of primary ICH. The incidence of cerebellar hemorrhage (CH) 
      exceeded that of other types of hemorrhage in patients taking ATs, and the 
      difference was statistically significant on bivariate analysis (P < .0001). On 
      multivariate analysis, only antiplatelet (AP) therapy was found to significantly 
      increase the frequency of CH in patients with primary ICH (P = .0035). Our 
      data indicate that taking APs before the onset of ICH a related factor for CH in 
      Japanese patients with primary ICH.
CI  - Copyright (c) 2011 National Stroke Association. Published by Elsevier Inc. All 
      rights reserved.
FAU - Matsukawa, Hidetoshi
AU  - Matsukawa H
AD  - Department of Neurosurgery, St Luke's International Hospital, Chuo-ku, Tokyo, 
      Japan. mahide@luke.or.jp
FAU - Shinoda, Masaki
AU  - Shinoda M
FAU - Yamamoto, Daisuke
AU  - Yamamoto D
FAU - Fujii, Motoharu
AU  - Fujii M
FAU - Murakata, Atsushi
AU  - Murakata A
FAU - Ishikawa, Ryoichi
AU  - Ishikawa R
FAU - Omata, Fumio
AU  - Omata F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100724
PL  - United States
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National 
      Stroke Association
JID - 9111633
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Cerebral Hemorrhage/*chemically induced/epidemiology
MH  - Chi-Square Distribution
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*adverse effects
MH  - Humans
MH  - Incidence
MH  - Japan/epidemiology
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2010/07/27 06:00
MHDA- 2011/09/10 06:00
CRDT- 2010/07/27 06:00
PHST- 2009/12/24 00:00 [received]
PHST- 2010/02/14 00:00 [revised]
PHST- 2010/02/15 00:00 [accepted]
PHST- 2010/07/27 06:00 [entrez]
PHST- 2010/07/27 06:00 [pubmed]
PHST- 2011/09/10 06:00 [medline]
AID - S1052-3057(10)00049-2 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2010.02.005 [doi]
PST - ppublish
SO  - J Stroke Cerebrovasc Dis. 2011 Jul-Aug;20(4):346-51. doi: 
      10.1016/j.jstrokecerebrovasdis.2010.02.005. Epub 2010 Jul 24.